SPAGNOLO, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.251
AS - Asia 829
EU - Europa 732
SA - Sud America 9
AF - Africa 5
OC - Oceania 4
Totale 7.830
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.239
SG - Singapore 426
CN - Cina 276
IT - Italia 235
FI - Finlandia 108
RU - Federazione Russa 80
FR - Francia 75
SE - Svezia 68
VN - Vietnam 51
DE - Germania 50
GB - Regno Unito 50
HK - Hong Kong 36
IN - India 14
IE - Irlanda 13
NL - Olanda 13
AT - Austria 11
PL - Polonia 9
BR - Brasile 7
TR - Turchia 7
CA - Canada 6
ES - Italia 5
MO - Macao, regione amministrativa speciale della Cina 5
UA - Ucraina 5
JP - Giappone 4
KG - Kirghizistan 3
MX - Messico 3
TW - Taiwan 3
AU - Australia 2
BE - Belgio 2
CH - Svizzera 2
DK - Danimarca 2
GH - Ghana 2
NZ - Nuova Zelanda 2
PT - Portogallo 2
SV - El Salvador 2
AM - Armenia 1
BG - Bulgaria 1
BO - Bolivia 1
CR - Costa Rica 1
EC - Ecuador 1
ID - Indonesia 1
IL - Israele 1
KE - Kenya 1
NO - Norvegia 1
SC - Seychelles 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 7.830
Salva come PNG Salva come JPEG
Città #
Fairfield 1.236
Woodbridge 651
Ashburn 568
Ann Arbor 477
Houston 461
Seattle 430
Cambridge 369
Chandler 344
Wilmington 322
Singapore 288
Boardman 190
San Diego 114
Medford 107
Princeton 106
Beijing 94
Santa Clara 84
Des Moines 70
Helsinki 60
Dong Ket 50
Roxbury 45
Padova 36
Hong Kong 33
London 18
Nanjing 17
Rome 17
New York 16
Nuremberg 16
Dublin 13
Milan 13
Guangzhou 12
Los Angeles 12
Nanchang 12
Jinan 11
Ogden 10
Lappeenranta 9
Dallas 8
Washington 8
Kilburn 7
Pune 7
Tianjin 7
Vienna 7
Kunming 6
Orange 6
Shenyang 6
Turin 6
Zabrowo 6
Macao 5
Munich 5
Council Bluffs 4
Falls Church 4
Florence 4
Fuzhou 4
Hebei 4
Hefei 4
Hounslow 4
Jiaxing 4
Naples 4
Redwood City 4
Sant'Anastasia 4
Bishkek 3
Brendola 3
Fossò 3
Rovigo 3
Shanghai 3
Siracusa 3
Walnut 3
Zhengzhou 3
Accra 2
Albacete 2
Amsterdam 2
Bari 2
Bhopal 2
Bussero 2
Cagliari 2
Changsha 2
Chianciano Terme 2
Chiswick 2
Crotone 2
Hyderabad 2
Istanbul 2
Kharkiv 2
Madrid 2
Magdeburg 2
Mahbubnagar 2
Mexico City 2
Modena 2
Montreal 2
New Bedfont 2
Pavia 2
Pinehaven 2
Podenzana 2
Porcari 2
Predaia - Campodenno 2
Recco 2
Redmond 2
San Francisco 2
San Salvador 2
Sapporo 2
Schio 2
St Petersburg 2
Totale 6.529
Salva come PNG Salva come JPEG
Nome #
High-Resolution CT Change over Time in Patients with Idiopathic Pulmonary Fibrosis on Antifibrotic Treatment 151
Immune inflammation and disease progression in idiopathic pulmonary fibrosis 134
Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF) 131
Abandoning developmental silos: what can paediatricians and adult interstitial lung disease physicians learn from each other? 127
The Lung in Rheumatoid Arthritis: Focus on Interstitial Lung Disease 126
A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis 113
Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) Syndrome and Carcinoid Tumors With/Without NECH 112
High-Resolution Computed Tomography (HRCT) Reflects Disease Progression in Patients with Idiopathic Pulmonary Fibrosis (IPF): Relationship with Lung Pathology 111
Research highlights from the 2018 ERS International Congress: interstitial lung diseases 103
Diagnostic Likelihood Thresholds that Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis 100
Acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF): an overview of current and future therapeutic strategies 97
Recent advances in the pathobiology and clinical management of lymphangioleiomyomatosis 96
Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis 94
Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis 94
Immunogenetics of Disease-Causing Inflammation in Sarcoidosis 92
Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives 92
Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy 91
IPF in 2016: towards a better diagnosis 91
New guideline on treatment of idiopathic pulmonary fibrosis 90
CA 19-9 serum levels in patients with end-stage idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILDs): Correlation with functional decline 89
Update on therapeutic management of idiopathic pulmonary fibrosis 88
Pathogenesis of idiopathic pulmonary fibrosis and its clinical implications 88
Sarcoidosis: a Critical Review of History and Milestones 87
Pharmacological management of IPF 87
Interstitial lung disease in children younger than 2 years 87
Endobronchial ultrasound-guided transbronchial needle aspiration in sarcoidosis: Beyond the diagnostic yield 87
The Role of the Lung's Microbiome in the Pathogenesis and Progression of Idiopathic Pulmonary Fibrosis 86
Matriptase, protease-activated receptor 2, and idiopathic pulmonary fibrosis: Further evidence for signaling pathway redundancy in this difficult-to-treat disease? 85
Imaging aspects of the diagnosis of sarcoidosis 85
Diagnosis and Management of Asthma - The Swiss Guidelines 84
Accuracy of individual in the monitoring of long term change in pulmonary sarcoidosis as judge by serial HRCT data 83
Differential diagnosis of usual interstitial pneumonia: When is it truly idiopathic? 83
Novel Treatments for Idiopathic Pulmonary Fibrosis 82
Critical review of the evolution of extracellular vesicles’ knowledge: From 1946 to today 82
Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: A pooled analysis 81
An important step forward, but still a way to go 81
Pharmacological treatment of idiopathic pulmonary fibrosis: An update 80
Idiopathic pulmonary fibrosis: An update 80
Chickenpox-Related Multiple Pulmonary Granulomas: A Poorly Recognized Entity 80
Treatment effect of idebenone on inspiratory function in patients with Duchenne muscular dystrophy 79
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia syndrome 79
Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist 78
Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary Fibrosis 78
Connective tissue diseases, multimorbidity and the ageing lung 77
Pulmonary sarcoidosis 77
Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy 75
Characterization of pulmonary function in 10–18 year old patients with Duchenne muscular dystrophy 75
Daily home spirometry: A new milestone in the field of pulmonary fibrosis 74
Genetics of idiopathic pulmonary fibrosis: From mechanistic pathways to personalised medicine 73
Biopsy in idiopathic pulmonary fibrosis: back to the future 72
Classification of different patterns of pulmonary adenocarcinomas 72
Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis 70
Hemoptysis and progressive dyspnea in a 67-year-old woman with history of renal transplantation 70
Clinical Features and Chest Imaging as Predictors of Intensity of Care in Patients with COVID-19 70
Recurrent cerebrospinal fluid basophilia in neurosarcoidosis 69
Genetic determinants of pulmonary fibrosis: Evolving concepts 68
Association between leukocyte telomere length (LTL) and functional decline in patients with Idiopathic Pulmonary Fibrosis (IPF) on antifibrotic treatment 68
Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities 67
Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy 66
Patients with IPF and lung cancer: diagnosis and management 65
Ventilatory support and mechanical properties of the fibrotic lung acting as a “squishy ball” 64
Pharmacological treatment of idiopathic pulmonary fibrosis: An update 63
Serious adverse events in patients with idiopathic pulmonary fibrosis in the placebo arms of 6 clinical trials 63
Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: An international case-cohort study 62
The Diagnostic Yield of the Multidisciplinary Discussion in Patients With COVID-19 Pneumonia 62
Pulmonary fibrosis secondary to COVID-19: a call to arms? 60
Large cell neuroendocrine carcinoma of the lung: chemotherapy regimen depends on how "large" your diagnostic criteria are 59
The Ariane-IPF ERS Clinical Research Collaboration: seeking collaboration through launch of a federation of European registries on idiopathic pulmonary fibrosis 59
Prognostic role of MUC5B rs35705950 genotype in patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment 58
Clinical differences in sarcoidosis patients with and without lymphoma: a single-center retrospective cohort analysis 57
Shedding light on developmental drugs for idiopathic pulmonary fibrosis 57
Clinical trial research in focus: why do so many clinical trials fail in IPF? 55
The role of macrophages in interstitial lung diseases 55
Interstitial lung disease with and without progressive fibrosing phenotype in patients with idiopathic inflammatory myopathies: data from a large multicentric cohort 54
Genetics of sarcoidosis 54
Pirfenidone and mortality in idiopathic pulmonary fibrosis 54
Thoracic Involvement in Systemic Autoimmune Rheumatic Diseases: Pathogenesis and Management 54
Treatment effect of idebenone on inspiratory function in patients with Duchenne muscular dystrophy 53
The management of patients with idiopathic pulmonary fibrosis 53
Disease Severity and Prognosis of SARS-CoV-2 Infection in Hospitalized Patients Is Not Associated With Viral Load in Nasopharyngeal Swab 53
Hypersensitivity pneumonitis: A comprehensive review 52
The value of chest radiograph and computed tomography in pulmonary sarcoidosis 51
Subclinical liver fibrosis in patients with idiopathic pulmonary fibrosis 51
Idiopathic pulmonary fibrosis: Disease mechanisms and drug development 51
Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone 49
Acute exacerbations of interstitial lung disease: Lessons from idiopathic pulmonary fibrosis 47
Chronic Bronchitis Affects Outcomes in Smokers without Chronic Obstructive Pulmonary Disease (COPD) 45
Characteristics and Prognostic Factors of Pulmonary Fibrosis After COVID-19 Pneumonia 44
Challenges in Cardiac and Pulmonary Sarcoidosis: JACC State-of-the-Art Review 44
Massive lung calcifications in a four times renal transplanted patient: the fight against dialysis, hyper and hypoparathyroidism 44
Hypersensitivity pneumonitis 43
Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs) 42
Is the imaging inconsistent with usual interstitial pneumonia? Think about idiopathic pulmonary fibrosis then! 40
Chest x-ray or CT for COVID-19 pneumonia? Comparative study in a simulated triage setting 40
Personalized medicine in idiopathic pulmonary fibrosis: Facts and promises 39
Brief communication: Chest radiography score in young COVID-19 patients: Does one size fit all? 38
Pulmonary Sarcoidosis: Diagnosis and Differential Diagnosis. 37
Arrhythmias in Cardiac Sarcoidosis Bench to Bedside: A Case-Based Review 36
Genome-wide association studies in idiopathic pulmonary fibrosis: Bridging the gap between sequence and consequence 35
When the Game Changes: Guidance to Adjust Sarcoidosis Management During the Coronavirus Disease 2019 Pandemic 35
Totale 7.264
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.407
article - articoli 39.670
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 80.077
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020634 0 0 0 0 0 0 0 182 184 127 93 48
2020/20211.211 43 61 59 60 24 24 239 71 184 234 105 107
2021/20221.517 62 126 235 75 120 75 61 193 146 43 95 286
2022/2023810 184 18 22 86 163 97 1 52 139 6 34 8
2023/2024702 18 86 70 50 51 77 53 45 28 37 109 78
2024/20251.135 12 217 135 117 320 68 192 74 0 0 0 0
Totale 8.088